MedicineEndocrinologyPharmacotherapyBone AugmentationBone MetabolismCalcium HomeostasisBone Metabolism DisordersBone Metabolism PharmacotherapyCalcitonin PhysiologyDisorders Of Calcium MetabolismOsteogenesisOsteogenesis ImperfectaBone Resorption InhibitionBone Resorption MarkersCalcitonin PharmacologyHydroxyproline ContentPaget Disease TherapySubcutaneous DosingSymptomatic TherapyUrinary Calcium Excretion
Synthetic salmon calcitonin was given daily for 90 days as a subcutaneous dose of 50 Medical Research Council units to three patients with active Paget's disease and one patient with osteogenesis imperfecta. Symptomatic improvement occurred in two of the patients with Paget's disease and in the patient with osteogenesis imperfecta. During the three months of treatment, serum alkaline phosphatase, urinary hydroxyproline, and urinary calcium decreased significantly in the patients with Paget's disease, and, in the patient with osteogenesis imperfecta, urinary hydroxyproline decreased, suggesting that this new form of calcitonin is also effective in reducing bone resorption in these diseases. No adverse reactions were observed in our initial studies.
19